Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.

Shaji K Kumar Angela DispenzieriDivaya BhutaniMorie A GertzAshutosh WechalekarGiovanni PalladiniRaymond ComenzoRafael FonsecaArnaud JaccardEfstathios KastritisStefan O SchönlandCharles la PorteHuiling PeiNamPhuong TranGiampaolo Merlini

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2023)

These results support the use of D-VCd as standard of care in patients with newly diagnosed AL amyloidosis regardless of cytogenetic abnormalities.

Keyphrases

newly diagnosed
healthcare
multiple myeloma
palliative care
quality improvement
pain management
chronic pain